TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18638410
Drug: Osteopathy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathy treatment (n = 15 infants)
Study: 7730703
Drug: 18 monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 monthly doses of WHO/MDT
Study: 7730703
Drug: 30 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30 monthly doses of WHO/MDT
Study: 2210598
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine orally one hour prior to anesthetic induction
Study: 2210598
Drug: Nifedipine infusion
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine infusion of 0.30 micron/kg/min prior to extracorporeal circulation
Study: 2210598
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nifedipine infusion)
Study: 7378259
Drug: Debrisoquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debrisoquine (30 mg oral dose)
Study: 7378259
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg p.o.) given 2 h before debrisoquine
Study: 7378259
Drug: Chronic debrisoquine
Normalized name: Debrisoquine
DrugBank: Debrisoquine (DB04840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic debrisoquine therapy
Study: 31111502
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (PRT) with a median dose of 73.8 Gy (RBE; range 68.4-79.2 Gy); 17 patients received adjuvant PRT, 3 received definitive PRT; PRT-only (n=6) or combination PRT/intensity-modulated radiotherapy (IMRT) (n=14)
Study: 28641030
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg E4 combined with 3 mg DRSP
Study: 28641030
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg E4 combined with 3 mg DRSP
Study: 28641030
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg E4 combined with 150 μg LNG
Study: 28641030
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg E4 combined with 150 μg LNG
Study: 23748252
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg twice per day) and celecoxib (100 mg twice per day) for 14 days before THA and for three weeks after discharge.
Study: 21426884
Drug: 1,600 mg
Normalized name: omega-3/dha/epa/fish oil 1,600 mg-500 mg-800 mg/5 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,600 mg of MESNA plus 0.9% saline
Study: 20052918
Drug: Cycloferon addition
Normalized name: Cicloferon
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloferon addition to main therapy
Study: 20052918
Drug: Main therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Main therapy without cycloferon
Study: 18411913
Drug: Hormonal supplement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal supplement therapy per oss (HST)
Study: 18411913
Drug: Transdermal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo (Control)
Study: 15132876
Drug: Phenoxybenzamine-hydrochloride: 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine-hydrochloride: 10 mg two times a day for one month
Study: 15132876
Drug: Flavoxate HCI-neptumus:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavoxate HCI-neptumus: 200 mg three times a day for one month
Study: 31322116
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g intravenous bolus followed by an 8‐hour 1‐g infusion)
Study: 20197354
Drug: Telemedicine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine treatment for 4 months
Study: 20197354
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for 4 months
Study: 20197354
Drug: Telemedicine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine treatment after conventional therapy
Study: 20197354
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment after telemedicine therapy
Study: 19347813
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and insulin concentrations in 0', 30', 60' of OGTT in obese women
Study: 12050268
Drug: rhIGF‐I (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (30 microg/kg sc twice daily) and oral contraceptive (Ovcon 35, 35 microg ethinyl estradiol and 0.4 mg norethindrone)
Study: 12050268
Drug: rhIGF‐I alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I alone (30 microg/kg sc twice daily)
Study: 12050268
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive alone
Study: 12050268
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active therapy
Study: 1375685
Drug: Anistreplase (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase (doses ranging from 3.75 to 35 IU, 60% received 30 IU)
Study: 1375685
Drug: Delay from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay from onset of symptoms to treatment
Study: 25985403
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir (PrEP)
Study: 3455212
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (ST)
Study: 3455212
Drug: Non-steroid treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid treatment (NT)
Study: 16814890
Drug: Fermented millet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented millet drink (KSW) 300 ml daily for 5 days
Study: 16814890
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for diarrhoea at local clinic
Study: 7944428
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of ADM or MMC
Study: 7944428
Drug: No regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No regional chemotherapy
Study: 7944428
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 5-FU
Study: 7944428
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local chemotherapy
Study: 3232498
Drug: Nalbuphine 20
Normalized name: nalbuphine 20 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 20 mg I.M.
Study: 3232498
Drug: Pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 30 mg I.M.
Study: 25276627
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1g)
Study: 20822500
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg of polaprezinc in addition to standard therapies
Study: 20822500
Drug: Standard therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapies only
Study: 7520857
Drug: Appetite stimulants
Normalized name: APPETITE STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appetite stimulants (specifics not provided)
Study: 7520857
Drug: Enteral and
Normalized name: Enteral and supplement feeds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral and parenteral alimentation (under evaluation)
Study: 28050704
Drug: Swallowing action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing action immediately before intravenous fentanyl (S group)
Study: 19674724
Drug: Maximum limit
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum limit statements (e.g., maximum distances, maximum durations, maximum prices, maximum delivery times)
Study: 17344008
Drug: Brachytherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy with Ir-192 (mean dose 30 Gy) and external radiotherapy (mean dose 50 Gy)
Study: 11303344
Drug: Anti-reflux treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-reflux treatment in reflux positive HRAD patients
Study: 11303344
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for reflux in reflux negative HRAD patients
Study: 7988260
Drug: CAP (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP (cyclophosphamide, doxorubicin, cisplatin) chemotherapy plus radiation therapy as preoperative or neoadjuvant therapy
Study: 2691239
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support diet (50 kcal/kg bodyweight/d and 1.5 g protein/kg bodyweight/d)
Study: 21929600
Drug: Continuous sublingual
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sublingual immunotherapy (SLIT)
Study: 21929600
Drug: Coseasonal sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coseasonal sublingual immunotherapy (SLIT)
Study: 15706659
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg OW
Study: 15706659
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg OW
Study: 9129791
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension (1 ml of phosphate‐buffered saline)
Study: 26939828
Drug: Bioptron light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioptron light therapy + cryotherapy
Study: 31209191
Drug: Oral Na/K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Na/K citrate plus saline infusion (treatment group)
Study: 31209191
Drug: Oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral water plus saline infusion (placebo group)
Study: 31209191
Drug: CIN-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIN-positive patients in treatment group
Study: 27889832
Drug: Selumetinib 25
Normalized name: selumetinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib 25 mg co-administered with itraconazole 200 mg twice daily (study A)
Study: 27889832
Drug: Selumetinib 25
Normalized name: selumetinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib 25 mg co-administered with fluconazole 400 mg on day 1 then 200 mg/day (study A)
Study: 27889832
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg co-administered with rifampicin 600 mg/day (study B)
Study: 27889832
Drug: Selumetinib 25
Normalized name: selumetinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib 25 mg alone (study A)
Study: 27889832
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg alone (study B)
Study: 27889832
Drug: Selumetinib co-administered
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib co-administered with itraconazole (study A)
Study: 27889832
Drug: Selumetinib co-administered
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib co-administered with rifampicin (study B)
Study: 27889832
Drug: Selumetinib co-administered
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib co-administered with fluconazole (study A)
Study: 23656463
Drug: Soy supplement
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplement diet (Soy Group, SG; n = 72)
Study: 23656463
Drug: Casein supplement
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein supplement diet (Casein Group, CG; n = 68)
Study: 19622007
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + colesevelam HCl
Study: 19622007
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + matching placebo
Study: 17597499
Drug: Ganoderma lucidum
Normalized name: GANODERMA LUCIDUM STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganoderma lucidum extract (2 grams, twice daily for 10 days)
Study: 15080351
Drug: 10% povidone-iodine
Normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% povidone-iodine solution applied 3 times at 2-month intervals (N = 13)
Study: 15080351
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group, N = 12)
Study: 9895085
Drug: Sameridine 0.73
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sameridine 0.73 mg/kg (S-Large)
Study: 9895085
Drug: Sameridine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sameridine 0.15 mg/kg (S-Small)
Study: 9895085
Drug: Morphine 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.10 mg/kg
Study: 3710663
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g daily for 3 weeks)
Study: 10389804
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 10 mg
Study: 29413502
Drug: Lebrikizumab 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 125 mg subcutaneously (SC)
Study: 29413502
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg orally
Study: 26771423
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate (500 mg/d)
Study: 26771423
Drug: Calcium Phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Phosphate (500 mg/d)
Study: 17922130
Drug: Triadcortyl (TAC)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triadcortyl (TAC) ointment
Study: 17922130
Drug: 10% glycerine-ichthammol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycerine-ichthammol (GI) solution
Study: 3113778
Drug: TRH infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH infusion (5 micrograms/min)
Study: 3113778
Drug: D-Ala2-MePhe4-met-enkephalin-0-ol (DAMME)
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-Ala2-MePhe4-met-enkephalin-0-ol (DAMME) bolus (250 micrograms) after TRH infusion
Study: 3113778
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion with DAMME bolus
Study: 3113778
Drug: TRH infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH infusion alone
Study: 3113778
Drug: TRH infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH infusion with DAMME bolus
Study: 22515556
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose, 90 mg twice daily maintenance dose)
Study: 22515556
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose, 75 mg once daily maintenance dose)
Study: 19812099
Drug: Clinical pathways
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pathways (CP) for hospital treatment of HF
Study: 16333533
Drug: 2x treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x treatment
Study: 9352604
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of rhenium-186
Study: 9352604
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of rhenium-186 in combination with triamcinolone hexacetonide
Study: 9352604
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of triamcinolone hexacetonide alone
Study: 8239200
Drug: Albumin replacement
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin replacement to a level greater than or equal to 3.5 g/dL (AR group)
Study: 10365287
Drug: Inogatran (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (all doses)
Study: 7497776
Drug: Dopexamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (1 mg.kg‐1.min‐1)
Study: 7497776
Drug: Dopamine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (2.5 mg.kg‐1.min‐1)
Study: 1674295
Drug: Desferrioxamine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine (125 mg intramuscularly twice daily, 5 days per week, for 24 months)
Study: 1674295
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (lecithin)
Study: 7178257
Drug: Daily exposures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exposures to hot and humid conditions (D: 43 degrees C, 32 Torr, 165 min)
Study: 21899583
Drug: Probiotical (synbiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotical (synbiotic food supplement)
Study: 15134183
Drug: Indinavir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 600 mg + Ritonavir 100 mg twice daily
Study: 15134183
Drug: Indinavir 400
Normalized name: indinavir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 400 mg + Ritonavir 100 mg twice daily
Study: 9254875
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (monophasic in 9 patients, biphasic in 5 patients)
Study: 9254875
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (biphasic)
Study: 8015885
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid (50 mg, 3.7 +/- 0.9 mg/kg)
Study: 8015885
Drug: Acetaminophen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (100 mg, 7.7 +/- 1.7 mg/kg)
Study: 3619710
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol (160 mg/d)
Study: 3619710
Drug: Primidone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primidone (250 mg at night)
Study: 3619710
Drug: Clonazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (4 mg/d)
Study: 23832723
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus Simvastatin (combination group)
Study: 18208570
Drug: interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: interferon alfa-2a (3 million units three times weekly)
Study: 25725564
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid (ITS) initial treatment (ITSi)
Study: 25725564
Drug: Intratympanic salvage
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic salvage treatment (ITSs)
Study: 16847412
Drug: Uridine-enriched food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uridine-enriched food supplement NucleomaxX
Study: 14657844
Drug: Topical calcineurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcineurin inhibitors
Study: 14657844
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy and early intervention
Study: 11464618
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for Helicobacter pylori infection
Study: 30547305
Drug: High-flexion TKA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flexion TKA implant
Study: 29763676
Drug: Real dual-tDCS
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real dual-tDCS (anodal over the lesioned hemisphere, cathodal over the non-lesioned hemisphere) at 2-mA intensity for 20 minutes followed by conventional physical therapy
Study: 29763676
Drug: Sham dual-tDCS
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham dual-tDCS followed by conventional physical therapy
Study: 29763676
Drug: Real dual-tDCS
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real dual-tDCS and conventional physical therapy
Study: 24662947
Drug: E10A plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: E10A plus chemotherapy (cisplatin and paclitaxel)
Study: 22664749
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 600 mg
Study: 22664749
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 1800 mg
Study: 22664749
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 2400 mg
Study: 17549429
Drug: Medication (MED)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (MED) (oxybutynin ER)
Study: 9797978
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment combining two therapies
Study: 9797978
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment designed to mimic experimental treatment
Study: 8106774
Drug: GenHevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenHevac B vaccine (G), 20 micrograms/dose
Study: 8106774
Drug: Hevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hevac B vaccine (H), 5 micrograms/dose
Study: 8106774
Drug: GenHevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenHevac B vaccine (G), after booster at month 12